Scioderm’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Scioderm is a pharmaceutical company that develops topical products for the treatment of chronic skin diseases. Read more

Scioderm is a pharmaceutical company that develops topical products for the treatment of chronic skin diseases. Read more

Robert Ryan's photo - CEO of Scioderm

CEO

Robert Ryan

CEO Approval Rating

69/100

Founded:

06/2012

Status:

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Shire is a top competitor of Scioderm. Shire is a Private company that was founded in 1986 in Zug, Zug. Shire operates in the Pharmaceuticals industry. Compared to Scioderm, Shire has 22,988 more employees.

Amicus Therapeutics, Inc. is seen as one of Scioderm's biggest rivals. Amicus Therapeutics, Inc. was founded in 2002, and is headquartered in Cranbury, New Jersey. Amicus Therapeutics, Inc. operates in the Biotechnology industry. Amicus Therapeutics, Inc. generates $206.5M more revenue vs. Scioderm.

Sanofi is seen as one of Scioderm's top competitors. Sanofi was founded in Paris, Île-de-France} in 1994. Sanofi competes in the Pharmaceuticals industry. Compared to Scioderm, Sanofi generates $40.4B more revenue.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 56 a good estimate for Scioderm's Employee count?

Acquisitions

No recent acquisitions found related to Scioderm

Scioderm Funding History

$17M$37M

Since Scioderm was founded in 06/2012, it has participated in 3 rounds of funding. In total Scioderm has raised $37.0M. Scioderm's last funding round was on Dec 2014 for a total of $20.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series B
Dec 2014
$20M
Series A
Apr 2013
$16M
Unattributed
Mar 2013
$1M
-

Total Funding: $37M

Since Scioderm was founded in 06/2012, it has participated in 3 rounds of funding. In total Scioderm has raised $37.0M. Scioderm's last funding round was on Dec 2014 for a total of $20.0M

Investments

No recent investments found related to Scioderm

Scioderm News

February 1, 2016The Business Journals: Raleigh/Durham

After Scioderm, Robert Ryan enters into second act

Robert Ryan will give it another go. Ryan is the former co-founder and chief executive of Scioderm, I... See more »
December 30, 2015The Business Journals: Raleigh/Durham

Scioderm founder Rob Ryan exits company after acquisition

Robert Ryan, who founded the drug developer Scioderm and saw it through an acquisition that could ult... See more »
September 30, 2015BIOSPACE

Amicus Completes Acquisition Of Scioderm

css" rel"stylesheet" href"http://www.globenewswire.com/styles/gnw_nitf.css" />CRANBURY, N.J., Sept. 3... See more »
September 3, 20154-TRADERS

Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)

(4-traders.com) Item 1.01 Entry into a Material Definitive Agreement. On August 30, 2015, Amicus Ther... See more »
September 2, 2015TRIANGLE BUSINESS JOURNAL

Can Durham's Scioderm reach the $1 billion carrot?

Small Triangle drug developer Scioderm Inc. reached a deal with Amicus Therapeutics (Nasdaq: FOLD) th... See more »
September 1, 20154-TRADERS

to acquire Durham's Scioderm for up to $947M

(4-traders.com) Aug. 31--A Durham life sciences startup developing a medication for a rare skin disor... See more »
August 31, 2015TRIANGLE BUSINESS JOURNAL

Durham drug developer sold to Amicus Therapeutics in deal worth up to $947M

Small drug developer Scioderm Inc. made a big splash Monday when it sold to Amicus Therapeutics (Nasd... See more »

Scioderm Press Releases

March 19, 2015BUSINESS WIRE

Scioderm Initiates Phase 3 Registration Trial of ZorblisaTM (SD-101), a Novel Topical Therapy for Patients with Epidermolysis Bullosa

DURHAM, N.C.--(BUSINESS WIRE)--Scioderm Initiates Phase 3 Registration Trial of ZorblisaTM (SD-101), ... See more »
January 2, 2015PR NEWSWIRE

Scioderm to Present at 33rd Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Jan. 2, 2015 /PRNewswire/ -- Scioderm, Inc., today announced Robert Ryan, Ph.D., presid... See more »
July 30, 2014BUSINESS WIRE

Epidermolysis Bullosa - Pipeline Review, H1 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/br5skr/epid... See more »

Headquarters

1007 Slater Rd Suite 170

Durham, North Carolina27703

919-328-2020

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Scioderm is a pharmaceutical company that develops topical products for the treatment of chronic skin diseases. Scioderm was founded in 06/2012. Scioderm's headquarters is located in Durham, North Carolina, USA 27703. It has raised 37.0M in 3 rounds. ...

CEO

Scioderm's CEO, Robert Ryan, currently has an approval rating of 69%. Scioderm's primary competitors are Shire, Amicus Therapeutics, Inc. & Sanofi.

Website

sderm.com

Frequently Asked Questions about Scioderm

  1. When was Scioderm founded?

    Scioderm was founded in 06/2012
  2. Who is Scioderm's CEO?

    Scioderm's CEO is Robert Ryan
  3. How much revenue does Scioderm generate?

    Scioderm generates $9.3M in revenue
  4. How much funding does Scioderm have?

    Scioderm has historically raised $37M in funding
  1. Where is Scioderm's headquarters?

    Scioderm's headquarters is in Durham North Carolina, USA
  2. How many employees does Scioderm have?

    Scioderm has 56 employees
  3. What sector does Scioderm operate in?

    Scioderm is in Health Care Services
  4. Who are Scioderm's competitors?

    Scioderm's top competitors are Shire, Amicus Therapeutics, Inc., Sanofi